340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act, H.R.2670/S.2226/P.L.118-31;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1067, Ensuring Timely Access to Generics Act of 2023; S.1114, Expanding Access to Low-Cost Generics Act of 2023; S.1214, RARE Act; H.R.5378, Lower Costs, More Transparency Act; S.2840, Bipartisan Primary Care and Health Workforce Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP and supply chain; monitoring H.R.7085/S.3558, BIOSECURE Act.
Duration: March 1, 2017
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Copyright/Patent/Trademark , Trade (Domestic & Foreign)
Spending: about $1,550,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), U.S. Trade Representative (USTR), Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Katherine Dapper Staff Asst. Sen. Murray (D-WA)
Marc Numedahl LD Rep. Loebsack (D-IA), MLA Rep. Larsen (D-WA)
John Green Dep Chief of Staff/Leg Aide, Senator Trent Lott
Chris Miller CoS Rep. Reichert (R-WA), Senior LA Rep. Miller (R-CA), Staff Asst. Sen. Smith (R-OR)
Chief of Staff/Legislative Director, Rep. Reichert; Senior Legislative Asst, Rep. Miller; Legislative Asst, Rep. Dunn; LC, Sen. Hutchinson; Staff Asst, Sen. Smith
Salim Alameddin Legislative Asst/Legislative Aide, Rep. Will Hurd; Legislative Correspondent/Staff Asst, Sen. John Cornyn
Jason Gleason Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes
Rontel Batie Legislative Assistant, Aide, Intern, Rep. Corrine Brown
Alex Gleason Legislative Assistant, Legislative Aide, Legislative Correspondent, Rep. Ed Royce; Intern, Rep. Aaron Schock
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Thomas J. Lucas Legislative Assistant, Legislative Aide, Legislative Correspondent, Staff Assistant: Senator Joe Manchin III
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
Mathew Lapinski n/a
Stewart Hall n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 22.
Original Filing: 301573745.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act, H.R.2670/S.2226/P.L.118-31;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1067, Ensuring Timely Access to Generics Act of 2023; S.1114, Expanding Access to Low-Cost Generics Act of 2023; S.1214, RARE Act; H.R.5378, Lower Costs, More Transparency Act; S.2840, Bipartisan Primary Care and Health Workforce Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; monitoring H.R.7085/S.3558, BIOSECURE Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 20.
Original Filing: 301533751.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act, H.R.2670/S.2226;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1067, Ensuring Timely Access to Generics Act of 2023; S.1114, Expanding Access to Low-Cost Generics Act of 2023; S.1214, RARE Act; H.R.5378, Lower Costs, More Transparency Act; S.2840, Bipartisan Primary Care and Health Workforce Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023; Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301514050.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act, H.R.2670/S.2226;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1067, Ensuring Timely Access to Generics Act of 2023; S.1114, Expanding Access to Low-Cost Generics Act of 2023; S.1214, RARE Act; H.R.5378, Lower Costs, More Transparency Act; S.2840, Bipartisan Primary Care and Health Workforce Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 19, 2023.
Original Filing: 301484435.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; S.1067, Ensuring Timely Access to Generics Act of 2023; S.1114, Expanding Access to Low-Cost Generics Act of 2023; S.1214, RARE Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
H.R.3746, Fiscal Responsibility Act of 2023;
H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 19, 2023.
Original Filing: 301457403.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance legislation; insulin price cap;
DoD TRICARE Pharmacy Benefits Program, FY2024 National Defense Authorization Act;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
H.R.830, HELP Copays Act;
S.127, Pharmacy Benefit Manager Transparency Act of 2023;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435254.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; antimicrobial resistance legislation; PDUFA Reauthorization; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
DoD TRICARE Pharmacy Benefits Program; FY2023 National Defense Authorization Act (H.R.7900, S.4543), S.4293, Pharmacy Benefit Manager Transparency Act of 2022.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; S.2428, False Claims Amendments Act of 2021; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 19, 2022.
Original Filing: 301412495.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; education around COVID-19 therapies; antimicrobial resistance legislation; PDUFA Reauthorization; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
DoD TRICARE Pharmacy Benefits Program; FY2023 National Defense Authorization Act (H.R.7900, S.4543), S.4293, Pharmacy Benefit Manager Transparency Act of 2022.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301390002.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; education around COVID-19 therapies; antimicrobial resistance legislation; PDUFA Reauthorization; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
DoD TRICARE Pharmacy Benefits Program; FY2023 National Defense Authorization Act (H.R.7900), S.4293, Pharmacy Benefit Manager Transparency Act of 2022.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 19, 2022.
Original Filing: 301360793.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; education around COVID-19 therapies; antimicrobial resistance legislation; PDUFA Reauthorization; S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; S.3799, PREVENT Pandemics Act.
DoD TRICARE Pharmacy Benefits Program, FY2023 National Defense Authorization Act.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301327888.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; education around COVID-19 therapies; antimicrobial resistance legislation.
DoD TRICARE Pharmacy Benefits Program, FY2022 National Defense Authorization Act (H.R.4350, S.2792, S.1605, P.L.117-81).
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356, S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502, S.3062); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on Oct. 19, 2021.
Original Filing: 301306435.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; education around COVID-19 therapies; antimicrobial resistance legislation.
DoD TRICARE Pharmacy Benefits Program, FY2022 National Defense Authorization Act (H.R.4350/S.2792).
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); FY2022 Consolidated Appropriations Act (H.R.4502);
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on July 18, 2021.
Original Filing: 301279129.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; DoD TRICARE Pharmacy Benefits Program; education around COVID-19 therapies; antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301256387.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; DoD TRICARE Pharmacy Benefits Program; education around COVID-19 therapies; antimicrobial resistance legislation.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22) and SUPPORT for Patients and Communities Act (P.L.115-271).
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act;
H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240546.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; DoD TRICARE Pharmacy Benefits Program; education around COVID-19 therapies; COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1712/H.R.4100, DISARM Act of 2019.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; S.1895, Lower Health Care Costs Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212690.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; DoD TRICARE Pharmacy Benefits Program; education around COVID-19 therapies; COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1712/H.R.4100, DISARM Act of 2019.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Provisions related to supplemental appropriations and federal health programs;
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021;
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610), FY2021 Consolidated Appropriations Act (H.R.7608);
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 19, 2020.
Original Filing: 301193675.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain; TRICARE Pharmacy Program; education around COVID-19 therapies.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1895, Lower Health Care Costs Act of 2019.
S.1712/H.R.4100, DISARM Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6800, The Heroes Act.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding issues related to the pharmaceutical industry including opioid funding matters;
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on April 19, 2020.
Original Filing: 301172222.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising; international pharmaceutical supply chain.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1895, Lower Health Care Costs Act of 2019.
Education around COVID-19 therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.6201, Families First Coronavirus Response Act (P.L.116-127).
H.R.748, CARES Act (P.L.116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding issues related to the pharmaceutical industry including opioid funding matters;
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121675.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising.
TRICARE issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020 (P.L.116-92).
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding issues related to the pharmaceutical industry including opioid funding matters;
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure;
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968/S.2474, Department of Defense Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure;
H.R.1158, Consolidated Appropriations Act, 2020 (P.L.116-93);
H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072119.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising.
TRICARE issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding issues related to the pharmaceutical industry including opioid funding matters;
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968/S.2474, Department of Defense Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 20, 2019.
Original Filing: 301053161.xml
Lobbying Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; transparency; direct-to-consumer (DTC) advertising.
TRICARE issues in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020.
H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program; Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Funding issues related to the pharmaceutical industry including opioid funding matters;
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968, Department of Defense Appropriations Act, 2020, and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Biologic data exclusivity in the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on April 21, 2019.
Original Filing: 301033042.xml
Lobbying Issues
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; direct-to-consumer (DTC) advertising.
TRICARE issues in National Defense Authorization Act for Fiscal Year 2020.
H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019.
Implementation of SUPPORT for Patients and Communities Act (P.L.115-271).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets); Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6);
FY 2020 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
FY 2020 Department of Defense Appropriations;
Funding issues related to the pharmaceutical industry including opioid funding matters;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 19, 2019.
Original Filing: 301010992.xml
Lobbying Issues
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; direct-to-consumer (DTC) advertising;
H.R.2051, FAST Generics Act of 2017;
TRICARE issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232);
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2852/H.R.6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271);
H.R.6642, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets); Medicare Part B reimbursement; noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245);
Funding issues related to the pharmaceutical industry including opioid funding matters;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300993027.xml
Lobbying Issues
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; direct-to-consumer (DTC) advertising;
H.R.2051, FAST Generics Act of 2017;
Implementation of P.L.115-176, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017;
TRICARE issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019 (P.L.115-232);
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
H.R.6378, To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act;
H.R.6, SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare program (including Coverage Gap and other offsets); noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.6157/S.3159, Department of Defense Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245);
Funding issues related to the pharmaceutical industry including opioid funding matters;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300972878.xml
Lobbying Issues
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency;
H.R.2051, FAST Generics Act of 2017;
H.R.878, Trickett Wendler Right to Try Act of 2017/S.204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (P.L.115-176);
TRICARE issues in H.R.5515/S.2987, National Defense Authorization Act for Fiscal Year 2019;
S.2434, Animal Drug and Animal Generic Drug User Fee Amendments of 2018;
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare program (including Coverage Gap and other offsets); noninterference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
S.3158/House Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.6157/S.3159, Department of Defense Appropriations Act, 2019;
Funding issues related to the pharmaceutical industry including opioid funding matters;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on April 20, 2018.
Original Filing: 300952450.xml
Lobbying Issues
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
H.R.2051, FAST Generics Act of 2017.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.231/S.456, RACE for Children Act.
TRICARE issues in the FY19 National Defense Authorization Act.
S.2434, Animal Drug and Animal Generic Drug User Fee Amendments of 2018.
P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA).
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; reauthorization of the Children's Health Insurance Program (CHIP); opioid funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.849/S.260, Protecting Seniors' Access to Medicare Act of 2017, IPAB repeal;
Part D Medicare program (including Coverage Gap, IPAB repeal and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018); non-interference; Center for Medicare and Medicaid Innovation (CMMI); drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018;
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018;
H.R.3219/Senate, Department of Defense Appropriations Act, 2018;
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96);
H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123);
H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141);
Funding issues related to the pharmaceutical industry;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Jan. 21, 2018.
Original Filing: 300931822.xml
Lobbying Issues
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
H.R.2051, FAST Generics Act of 2017;
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017;
H.R.231/S.456, RACE for Children Act;
Implementation of National Defense Authorization Act for Fiscal Year 2017 and H.R.2810, National Defense Authorization Act for Fiscal Year 2018 (P.L.115-91), TRICARE issues;
340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; reauthorization of the Children's Health Insurance Program (CHIP).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.849/S.260, Protecting Seniors' Access to Medicare Act of 2017;
Part D Medicare program; non-interference; CMMI; IPAB repeal; drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018;
H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018;
H.R.3219/Senate, Department of Defense Appropriations Act, 2018;
H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes (P.L.115-90);
H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes;
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96);
Funding issues related to the pharmaceutical industry;
Waiver of PAYGO.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300908389.xml
Lobbying Issues
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017;
H.R.2051, FAST Generics Act of 2017;
H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52);
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017;
H.R.231/S.456, RACE for Children Act;
Implementation of National Defense Authorization Act for Fiscal Year 2017 and H.R.2810/Senate, National Defense Authorization Act for Fiscal Year 2018, TRICARE issues;
Reauthorization of Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biologics Drug User Fee Act (BDUFA); 340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency; Reauthorization of the Children's Health Insurance Program (CHIP).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.849/S.260, Protecting Seniors' Access to Medicare Act of 2017;
H.J.Res.51/S.J.Res.16/S.J.Res.17, Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act;
Part D Medicare program; non-interference; CMMI; IPAB repeal; drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3219, Department of Defense Appropriations Act, 2018; H.R.3354, Make America Secure and Prosperous Appropriations Act, 2018; funding issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300891900.xml
Lobbying Issues
H.R.2051, FAST Generics Act of 2017;
H.R.2430/S.934, FDA Reauthorization Act of 2017;
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017;
H.R.231/S.456, RACE for Children Act;
Implementation of National Defense Authorization Act for Fiscal Year 2017 and H.R.2810/Senate, National Defense Authorization Act for Fiscal Year 2018, TRICARE issues;
Reauthorization of Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biologics Drug User Fee Act (BDUFA); 340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; transparency.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.849/S.260, Protecting Seniors' Access to Medicare Act of 2017;
H.J.Res.51/S.J.Res.16/S.J.Res.17, Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act;
Part D Medicare program; non-interference; CMMI; IPAB repeal; drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); funding issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Crossroads Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $20,000. The report was filed on April 19, 2017.
Original Filing: 300870059.xml
Lobbying Issues
Reauthorization of Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biologics Drug User Fee Act (BDUFA); 340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare program; non-interference; CMMI; IPAB repeal; drug pricing; Valued-Based Payments; Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; funding issues related to the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
Crossroads Strategies, LLC filed a lobbying registration on March 31, 2017 to represent Pharmaceutical Research and Manufacturers of America, effective March 1, 2017.
Original Filing: 300862087.xml
Issue(s) they said they’d lobby about: Reauthorization of Prescription Drug User Fee Act (PDUFA), Generic Drug User Fee Act (GDUFA), and Biologics Drug User Fee Act (BDUFA); 340B drug discount program; truthful non-misleading industry communications; compassionate use/right to try; importation of biopharmaceuticals; drug pricing; Part D Medicare program; non-interference; CMMI; IPAB repeal; Valued-Based Payments; Medicare Part B reimbursement. FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; funding issues related to the pharmaceutical industry. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...